Cystic fibrosis (CF) is an autosomal recessive, life-limiting, genetically inherited disease. It is a multi-system disorder and results from one of several identified...
Added 15 days ago Drug news
Vertex has selected the triple combination of VX-445 (elexacaftor), tezacaftor and ivacaftor to submit for potential regulatory approvals for people ages 12 and older with cystic fibrosis.
Vertex Pharmaceuticals Incorporated announced that it has selected the triple combination of the next-generation corrector VX-445 (elexacaftor), tezacaftor and ivacaftor...
Added 1 month ago Drug news
Vertex Pharmaceuticals Incorporated announced the FDA approved Kalydeco (ivacaftor) for use in children with cystic fibrosis (CF) ages six months...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.
The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.
'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life.
Added 1 year ago
Specialised CF care has led to a dramatic improvement in survival in CF: in the last four decades, well above what was seen in the general population over the same period.
Added 5 years ago
Palliative care is an approach that improves quality of life for patients and their families facing problems associated with a life-threatening illness. Care planning is particularly important in CF...
Added 8 years ago
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.
Background: Ivacaftor is generally safe and effective in patients aged 2 years and older who have cystic fibrosis and specific CFTR mutations. We assessed its use in children aged 12 to <24 months.
Added 11 months ago
Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles.
Background: To determine in vivo effects of CFTR modulators on mutation S945L.
Added 1 year ago
- Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
- Credits available
- Registration required
- Subscription fee